Literature DB >> 30443844

The Gene Mutation Spectrum of Breast Cancer Analyzed by Semiconductor Sequencing Platform.

Yanhui Liu1, Bo Yang2, Xiaoyan Zhang2, Quanfei Huang3, Hailiang Liu4.   

Abstract

To use the semiconductor sequencing platform (SSP) to analyze the gene mutate spectrum of breast cancer patients. We recruited 46 breast cancer patients, and detected the ER/PR/HER2 expression level of the tumor tissue by immunohistochemistry. In addition, combined with SSP technology, we detected 207 hot mutation regions of 50 breast cancer related genes with multiple polymerase chain reaction (PCR) technology. There were 8 cases of grade I, 18 cases of grade II, 20 cases of grade III in 46 breast cancer patients according to histological grade and 12 cases of ER/PR + HER2 +, 18 cases of ER/PR + HER2-, 13 cases of ER/PR - HER2 +, 20 cases of ER/PR - HER2- according to ER/PR/HER2 status classification. Moreover, we found that there were 33 gene locus mutations of 8 genes including AKT1, APC, BRAF, CDKN2A, KRAS, PTEN, PIK3CA and TP53, but difference was not statistically significant (P > 0.05) when compared these gene mutations (except for PIK3CA) in each groups according to the histological classification of breast cancer and the ER/PR/HER2 classification. PIK3CA mutation rate of grade I was obviously higher than that of grade II ~ III histological grading in breast cancer patients (P < 0.05). Based on our results, we drew a conclusion that the occurrence and development of breast cancer was a process involved multiple genes. Here, we found that PIK3CA played a role in the development of the early stage of breast cancer, which could provide clinical basis for treatment of breast cancer. Moreover, SSP technology could be an effective and sensitive method for detection of gene mutation spectrum in breast cancer.

Entities:  

Keywords:  Breast cancer; Genetic screening; Mutate spectrum; Semiconductor sequencing platform (SSP)

Year:  2018        PMID: 30443844     DOI: 10.1007/s12253-018-0522-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  33 in total

Review 1.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

3.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

Authors:  Soonmyung Paik; Steven Shak; Gong Tang; Chungyeul Kim; Joffre Baker; Maureen Cronin; Frederick L Baehner; Michael G Walker; Drew Watson; Taesung Park; William Hiller; Edwin R Fisher; D Lawrence Wickerham; John Bryant; Norman Wolmark
Journal:  N Engl J Med       Date:  2004-12-10       Impact factor: 91.245

4.  CDKN2A-positive breast cancers in young women from Poland.

Authors:  Tadeusz Debniak; Cezary Cybulski; Bohdan Górski; Tomasz Huzarski; Tomasz Byrski; Jacek Gronwald; Anna Jakubowska; Elzbieta Kowalska; Oleg Oszurek; Steven A Narod; Jan Lubiński
Journal:  Breast Cancer Res Treat       Date:  2006-10-24       Impact factor: 4.872

Review 5.  Heterogeneity of breast cancer: etiology and clinical relevance.

Authors:  V Almendro; G Fuster
Journal:  Clin Transl Oncol       Date:  2011-11       Impact factor: 3.405

6.  Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Authors:  Reshma Ariga; Adil Zarif; Jocelyn Korasick; Vijaya Reddy; Kalliopi Siziopikou; Paolo Gattuso
Journal:  Breast J       Date:  2005 Jul-Aug       Impact factor: 2.431

7.  Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Authors:  Alfonso Sánchez-Muñoz; Elena Gallego; Vanessa de Luque; Luís G Pérez-Rivas; Luís Vicioso; Nuria Ribelles; José Lozano; Emilio Alba
Journal:  BMC Cancer       Date:  2010-04-13       Impact factor: 4.430

8.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

Review 9.  Breast cancer in China.

Authors:  Lei Fan; Kathrin Strasser-Weippl; Jun-Jie Li; Jessica St Louis; Dianne M Finkelstein; Ke-Da Yu; Wan-Qing Chen; Zhi-Ming Shao; Paul E Goss
Journal:  Lancet Oncol       Date:  2014-06       Impact factor: 41.316

10.  PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.

Authors:  S N Payne; M E Maher; N H Tran; D R Van De Hey; T M Foley; A E Yueh; A A Leystra; C A Pasch; J J Jeffrey; L Clipson; K A Matkowskyj; D A Deming
Journal:  Oncogenesis       Date:  2015-10-05       Impact factor: 7.485

View more
  1 in total

1.  Tspan8 is expressed in breast cancer and regulates E-cadherin/catenin signalling and metastasis accompanied by increased circulating extracellular vesicles.

Authors:  Maren Voglstaetter; Andreas R Thomsen; Jerome Nouvel; Arend Koch; Paul Jank; Elena Grueso Navarro; Tanja Gainey-Schleicher; Richa Khanduri; Andrea Groß; Florian Rossner; Carina Blaue; Clemens M Franz; Marina Veil; Gerhard Puetz; Andreas Hippe; Jochen Dindorf; Jubin Kashef; Wilko Thiele; Bernhard Homey; Celine Greco; Claude Boucheix; Andreas Baur; Thalia Erbes; Cornelius F Waller; Marie Follo; Ghamartaj Hossein; Christine Sers; Jonathan Sleeman; Irina Nazarenko
Journal:  J Pathol       Date:  2019-06-18       Impact factor: 7.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.